Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis

M. Lachnit, KZ. Revendova, P. Hradilek, R. Bunganic, Z. Koristek, T. Jelinek, M. Skutova, R. Piza, O. Volny, R. Hajek, M. Bar

. 2024 ; 168 (1) : 50-54. [pub] 20230616

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24005431

INTRODUCTION: Immunoablative therapy followed by autologous hematopoietic stem cell transplantation (AHSCT) is one of the possible disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS). In this case series, we would like to present six patients with MS, who underwent AHSCT as the first-line DMT. CASE REPORTS: Six MS patients with a rapid progression of disability with or without relapses underwent AHSCT as the first-line DMT at the University Hospital Ostrava between 2018 and 2021. The conditioning regimens for AHSCT used were a medium-intensity regime BEAM (Carmustine, Etoposid, Cytarabin, Melphalan) and low-intensity regime based on Cyclophosphamide. Four out of six patients showed some disability progression after AHSCT, so the rapid progression of MS was just slowed down by AHSCT. One patient developed activity on magnetic resonance imaging three months after AHSCT, and two experienced mild relapses during the follow-up period. None of our patients developed grade 4 non-hematological toxicity; all infections were mild. In one patient, an allergic reaction probably to dimethyl sulfoxide was observed. CONCLUSION: Our case series of 6 patients shows that AHSCT is a promising therapeutic approach to slow down the rapid progression of clinical disability in MS patients with a good safety profile.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005431
003      
CZ-PrNML
005      
20250408143435.0
007      
ta
008      
240404s2024 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2023.023 $2 doi
035    __
$a (PubMed)37337857
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Lachnit, Martin $u Department of Hematooncology, University Hospital Ostrava, Czech Republic $7 xx0330938
245    10
$a Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis / $c M. Lachnit, KZ. Revendova, P. Hradilek, R. Bunganic, Z. Koristek, T. Jelinek, M. Skutova, R. Piza, O. Volny, R. Hajek, M. Bar
520    9_
$a INTRODUCTION: Immunoablative therapy followed by autologous hematopoietic stem cell transplantation (AHSCT) is one of the possible disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS). In this case series, we would like to present six patients with MS, who underwent AHSCT as the first-line DMT. CASE REPORTS: Six MS patients with a rapid progression of disability with or without relapses underwent AHSCT as the first-line DMT at the University Hospital Ostrava between 2018 and 2021. The conditioning regimens for AHSCT used were a medium-intensity regime BEAM (Carmustine, Etoposid, Cytarabin, Melphalan) and low-intensity regime based on Cyclophosphamide. Four out of six patients showed some disability progression after AHSCT, so the rapid progression of MS was just slowed down by AHSCT. One patient developed activity on magnetic resonance imaging three months after AHSCT, and two experienced mild relapses during the follow-up period. None of our patients developed grade 4 non-hematological toxicity; all infections were mild. In one patient, an allergic reaction probably to dimethyl sulfoxide was observed. CONCLUSION: Our case series of 6 patients shows that AHSCT is a promising therapeutic approach to slow down the rapid progression of clinical disability in MS patients with a good safety profile.
650    _2
$a lidé $7 D006801
650    12
$a roztroušená skleróza $x terapie $x etiologie $7 D009103
650    _2
$a výsledek terapie $7 D016896
650    _2
$a příprava pacienta k transplantaci $x metody $7 D019172
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $x metody $7 D018380
650    _2
$a recidiva $7 D012008
655    _2
$a časopisecké články $7 D016428
700    1_
$a Revendová, Kamila $u Department of Neurology, University Hospital Ostrava, Czech Republic $u Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Czech Republic $7 xx0269360
700    1_
$a Hradílek, Pavel $u Department of Neurology, University Hospital Ostrava, Czech Republic $u Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Czech Republic $7 xx0076908
700    1_
$a Bunganič, Radovan $u Department of Neurology, University Hospital Ostrava, Czech Republic $u Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Czech Republic $7 xx0327527
700    1_
$a Kořístek, Zdeněk, $d 1967- $u Department of Hematooncology, University Hospital Ostrava, Czech Republic $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Czech Republic $7 xx0081998
700    1_
$a Jelínek, Tomáš, $d 1986- $u Department of Hematooncology, University Hospital Ostrava, Czech Republic $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Czech Republic $7 xx0230997
700    1_
$a Škutová, Monika $u Department of Neurology, University Hospital Ostrava, Czech Republic $7 xx0226220
700    1_
$a Píža, Radim $u Department of Neurology, University Hospital Ostrava, Czech Republic $7 xx0331033
700    1_
$a Volný, Ondřej, $u Department of Neurology, University Hospital Ostrava, Czech Republic $u Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Czech Republic $d 1986- $7 ola2015886726
700    1_
$a Hájek, Roman, $u Department of Hematooncology, University Hospital Ostrava, Czech Republic $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Czech Republic $d 1964- $7 nlk20000083645
700    1_
$a Bar, Michal, $u Department of Neurology, University Hospital Ostrava, Czech Republic $u Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Czech Republic $d 1965- $7 xx0047124
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 1 (2024), s. 50-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37337857 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20240404 $b ABA008
991    __
$a 20250408143432 $b ABA008
999    __
$a ok $b bmc $g 2295214 $s 1215191
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 168 $c 1 $d 50-54 $e 20230616 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK116 $a Pubmed-20240404

Najít záznam

Citační ukazatele

Možnosti archivace